首页 | 本学科首页   官方微博 | 高级检索  
检索        

强化免疫抑制治疗儿童再生障碍性贫血疗效分析
引用本文:麦惠容,黄绍良,陈纯,方建培,钟凤仪.强化免疫抑制治疗儿童再生障碍性贫血疗效分析[J].中国实用儿科杂志,2001,16(4):212-214.
作者姓名:麦惠容  黄绍良  陈纯  方建培  钟凤仪
作者单位:中山医科大学孙逸仙纪念医院儿科广州,510120
摘    要:探讨强化免疫抑制治疗儿童再生障碍性贫血(再障)的疗效。方法总结我院1991~1999年 儿童再障31例,根据治疗方法不同分3组对比观察基础治疗组(康力龙、654-2等),单用环孢菌素A(CSA)治 疗组,强化免疫抑制治疗组。结果基础治疗组、单用CSA组、强化免疫抑制治疗组有效率分别为27.27%,57.14%,76.92%;重型再障(SAA)有效率分别为11.11%,50.00%,75.00%;SAA-Ⅰ有效率分别为14.29%, 60.00%,88.89%。单用CSA组及强化免疫抑制治疗组疗效明显优于基础治疗组,强化免疫抑制组对SAA及 SAA-Ⅰ疗效更佳,有效率分别达75.00%和88.89%。结论以CSA为主的免疫抑制治疗比单用康力龙、654-2 等治疗更有效;对于SAA,CSA联合ALG/ATG、HDIVIG、HDMP等强化免疫治疗能提高疗效,对SAA-Ⅰ更明显。

关 键 词:贫血,再生障碍性免疫抑制治疗
文章编号:1005-2224(2001)04-0212-03
修稿时间:2000年10月30

Treatment of aplastic anemia with intensive immunosuppressive agents in children
Mai Huirong,Huang Shaoliang,Chen Chun,et al.Treatment of aplastic anemia with intensive immunosuppressive agents in children[J].Chinese Journal of Practical Pediatrics,2001,16(4):212-214.
Authors:Mai Huirong  Huang Shaoliang  Chen Chun  
Institution:Mai Huirong,Huang Shaoliang,Chen Chun,et al Department of Pediatrics,Sun Yet sen Memorial Hospital,Sun Yet sen University of Medical Sciences,Guangzhou 510120
Abstract:Objective To investigate the therapeutic effects of intensiveimmunosuppressive agents on aplastic anemia in children. Methods Thirty-one cases of aplastic anemia in children from 1991~1999 in our hospital were divided into three groups according to different treatment:Group A with fundamental therapy, such as stanzolol,654-2, etc.; Group B with cyclosporin A ( CSA ) and Group C with intensive immunosuppressive agents. Results The response rate of Group A,B,C was 27.27% ,57.14% and 76. 92% respectively. It was 11.11% ,50. 00% and 75.00% in SAA and 14.29%,60.00% and 88.89% in SAA- Ⅰ respectively. It was much more effective with therapy of CSA and intensive immunosuppressive agents than with fundamental therapy. The response rate of intensive immunosuppressive agents in SAA and SAA- Ⅰ was even higher. Conclusions It is more effective with immunosuppressive agents on the base of CSA than with fundamental therapy in treating aplastic anemia in children. CSA combined with ALG/ATG, HDIVIG and HDMP can increase the response rate in SAA, especially SAA- Ⅰ patients.
Keywords:Anemia  aplastic  Immunosuppressive agents
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号